(CercleFinance.com) – Novavax announces that it has obtained full marketing authorization (MA) from the European Commission for its Covid vaccine, Nuvaxovid (NVX-CoV2373).
This decision follows the favorable opinion for a full marketing authorization from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
The vaccine is now fully licensed for primary serial use in people ages 12 and older and as a booster dose in adults ages 18 and older for the prevention of COVID-19.
Nuvaxovid had initially obtained conditional marketing authorization in the EU for these indications.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
